id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2012-N-0218-0025,FDA,FDA-2012-N-0218,Advisory Committee; Antiviral Drugs Advisory Committee; Termination,Rule,Final Rule,2015-03-20T04:00:00Z,2015,3,2015-03-20T04:00:00Z,,2015-03-20T13:38:03Z,2015-06425,0,0,0900006481a53f08
FDA-2012-N-0218-0001,FDA,FDA-2012-N-0218,Antiviral Drugs Advisory Committee; Notice of Meeting,Notice,Meeting,2012-03-14T04:00:00Z,2012,3,2012-03-14T04:00:00Z,2012-05-18T03:59:59Z,2012-05-18T02:00:59Z,2012-06115,0,0,0900006480fd6e82